News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Pfizer Inc.'s Kidney Drug Also Slows Pancreatic Cancer
January 22, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Forbes -- Pfizer Inc., the world’s biggest drugmaker, said Friday a late-stage trial of Sutent reveals that the kidney cancer treatment also helps slow the growth of rare pancreatic neuroendocrine tumors.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Pfizer
MORE ON THIS TOPIC
Cancer
Cardiff Craters Amid Executive Exits, Mixed Mid-Stage Data
January 28, 2026
·
2 min read
·
Tristan Manalac
Podcast
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
January 28, 2026
·
1 min read
·
Heather McKenzie
GLP-1
Roche’s 22% Weight Loss Benefit Seals GLP-1’s Phase III Plans, Boosts Zealand Combo
January 27, 2026
·
2 min read
·
Annalee Armstrong
Duchenne muscular dystrophy
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
January 26, 2026
·
2 min read
·
Dan Samorodnitsky
